Health Evidence™ hosted a 60 minute webinar examining the effect of tobacco control policies on perinatal and child health. Click here for access to the audio recording for this webinar: https://youtu.be/pPXVfmJuLX0
Dr. Jasper Been, Consultant Neonatologist at the Erasmus University MC-Sophia Children’s Hospital and Honorary Research Fellow in the Centre for Medical Informatics at the University of Edinburgh led the session and presented findings from their recent systematic review and meta-analysis:
Faber T, Kumar A, Mackenbach J, Millett C, Basu S, Sheikh A, & Been JV. (2017). Effect of tobacco control policies on perinatal and child health: A systematic review and meta-analysis. The Lancet Public Health, 2(9), e420-e437.
Tobacco smoking and smoke exposure during pregnancy and childhood cause considerable childhood morbidity and mortality. This review examines the effect of tobacco control policies on perinatal and child health. Forty-one studies were included in the review. Implementation of smoke-free legislation was associated with reductions in rates of preterm birth, rates of hospital attendance for asthma exacerbations and rates of hospital attendance for all respiratory tract infections and for lower respiratory tract infections. Among two studies assessing the association between smoke-free legislation and perinatal mortality, one showed significant reductions in stillbirth and neonatal mortality but did not report the overall effect on perinatal mortality, while the other showed no change in perinatal mortality. Meta-analysis of studies on other MPOWER policies was not possible; all four studies on increasing tobacco taxation and one of two on offering disadvantaged pregnant women help to quit smoking that reported on our primary outcomes had positive findings. These findings provide strong support for implementation of such policies comprehensively across the world.
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
Effect of tobacco control policies on perinatal and child health: What's the evidence?
1. Welcome!
Effect of tobacco control
policies on perinatal and
child health: What's the
evidence?
You will be placed on hold until the webinar begins.
The webinar will begin shortly, please remain on the line.
2. Poll Questions: Consent
• Participation in the webinar poll questions is voluntary
• Names are not recorded and persons will not be identified in any way
• Participation in the anonymous polling questions is accepted as an
indication of your consent to participate
Benefits:
• Results inform improvement of the current and future webinars
• Enable engagement; stimulate discussion. This session is intended for
professional development. Some data may be used for program evaluation
and research purposes (e.g., exploring opinion change)
• Results may also be used to inform the production of systematic reviews
and overviews
Risks: None beyond day-to-day living
3. After Today
• The PowerPoint presentation and audio
recording will be made available
• These resources are available at:
– PowerPoint:
http://www.slideshare.net/HealthEvidence
– Audio Recording:
https://www.youtube.com/user/healthevidence
/videos
3
4. What’s the evidence?
Faber T, Kumar A, Mackenbach JP, Millett C,
Basu S, Sheikh A, & Been JV. (2017). Effect of
tobacco control policies on perinatal and child
health: A systematic review and meta-analysis.
The Lancet Public Health, 2(9), e420-e437.
https://healthevidence.org/view-
article.aspx?a=effect-tobacco-control-
policies-perinatal-child-health-systematic-
review-meta-32781
5. • Use CHAT to post comments /
questions during the webinar
– ‘Send’ questions to All (not
privately to ‘Host’)
• Connection issues
– Recommend using a wired
Internet connection (vs.
wireless)
• WebEx 24/7 help line
– 1-866-229-3239
Participant Side Panel in WebEx
Housekeeping
6. Housekeeping (cont’d)
• Audio
– Listen through your speakers
– Go to ‘Communicate > Audio Broadcast’
• WebEx 24/7 help line
– 1-866-229-3239
7. Poll Question #1
How many people are watching
today’s session with you?
A. Just me
B. 2-3
C. 4-5
D. 6-10
E. >10
8. Students:
Sarah Neil-Sztramko (Postdoctoral fellow)
Emily Belita (PhD candidate)
Patricia Burnett (PhD candidate)
Grace Thomas
Research Assistant
Rawan Farran
Research Assistant
Kristin Read
Research Coordinator
Heather Husson
Administrative Director
The Health Evidence™ Team
Maureen Dobbins
Scientific Director
Olivia Marquez
Research Coordinator
Maureen Dobbins
Scientific Director
Claire Howarth
Research Coordinator
Liz Kamler
Research Assistant
Emily Sully
Research Assistant
10. Why use www.healthevidence.org?
1. Saves you time
2. Relevant & current evidence
3. Transparent process
4. Supports for EIDM available
5. Easy to use
11. A Model for Evidence-
Informed Decision Making
National Collaborating Centre for Methods and Tools. (revised 2012). A
Model for Evidence-Informed Decision-Making in Public Health (Fact
Sheet). [http://www.nccmt.ca/pubs/FactSheet_EIDM_EN_WEB.pdf]
12. Stages in the process of
Evidence-Informed Public Health
National Collaborating Centre for Methods and Tools. Evidence-Informed
Public Health. [http://www.nccmt.ca/eiph/index-eng.html]
15. How often do you use systematic reviews
to inform a program/services?
A. Always
B. Often
C. Sometimes
D. Never
E. I don’t know what a systematic review is
Poll Question #3
16. Jasper V. Been
MD MPH PhD, Consultant Neonatologist at
the Erasmus University MC-Sophia Children’s
Hospital and Honorary Research Fellow in
the Centre for Medical Informatics at
The University of Edinburgh
53. - Two independent reviewers
- Customised data extraction forms
- Author contact if necessary
- Risk of bias: EPOC criteria
- Random-effects meta-analysis
- Overlapping populations excluded
54. - Sensitivity analyses
- Excluding high-risk-of-bias studies
- Including non-EPOC studies
- Subgroup analyses
- According to comprehensiveness of each policy
- Stratified by socioeconomic status
65. Health impact larger if legislation
more comprehensive
• Preterm birth-4%
• Asthma hospitalisations-10%
• Lower respiratory tract infection
hospitalisations
-18%
66. Health impact larger if legislation
more comprehensive
• Preterm birth-4%
• Asthma hospitalisations-10%
• Lower respiratory tract infection
hospitalisations
-18%
-5%
-12%
67. From: Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990
and 2013: Findings From the Global Burden of Disease 2013 Study
JAMA Pediatr 2016
-18%
-5%
68. Smoke-free legislation
Secondary outcomes
- Very preterm birth: –10.0% (95%CI –15.7 to –4.2)
- Low birth weight: –2.8% (95%CI –4.4 to –1.2)
- Small for gestational age: –1.8% (95%CI –3.2 to –0.5)
- Very small for gestational age: –0.6% (95%CI –0.6 to –0.6)
- Birth weight: +12.5g (95%CI +2.1 to +22.8)
Other secondary outcomes: no significant association
69. Help to quit tobacco use
Hawkins et al.
Prev Med 2016
Jarlenski et al.
Health Aff 2014
Massachusetts: tobacco cessation coverage
for Medicaid recipients (2006)
USA: optional medical enrollment policies
providing low-income women with stop
smoking services (among others)
– 6% decrease in upper respiratory tract
infection admissions
– No change in preterm birth
70. Tobacco taxation
Hawkins et al. Prev Med 2016Jarlenski et al. Health Aff 2014
Hawkins et al. JAMA Ped 2014Markowitz et al. J Hum Cap 2013
Landers. Am J Public Health 2014
Ma et al. Prev Chronic Dis 2013
Reduction in preterm birth among deprived
mothers in one of two studies
Reduction in asthma hospitalisations in two
out of three studies
–9% reduction in lower but not upper
respiratory tract infections per US$ increase in
state excise tax
71. Other policies and secondary outcomes
• Smoking cessation services for low-income pregnant
women
– Increased gestation length; no impact on SGA
• Tobacco taxation
– Reductions in LBW, SGA, increases in BW and
gestation
– Not consistent across studies
– Reductions in infant mortality in two studies
Adams et al. Medicaid Medicare Res Rev 2013
Jarlenski et al. Health Aff 2014
Hawkins et al. JAMA Ped 2014
Markowitz et al. J Hum Cap 2013Evans et al. J Public Econ 1999
Sen et al. Can Public Policy 2011 Patrick et al. Pediatrics 2016
72. Sensitivity/subgroup analyses
• Inclusion of non-EPOC studies
• Exclusion of high-risk-of-bias studies
• Some variation in association according to SES,
all showing pro-equity effect
73. Summary
• Smoke-free legislation associated with
reductions in preterm birth and
asthma/respiratory infection admissions
• Some studies also show reductions in
these outcomes following tax increases
• Very little information on child health
impact of other MPOWER policies
74. Strengths/limitations
• Strengths
– Pre-specified and peer-reviewed protocol
– Highly comprehensive search strategy
– Considerable number of studies + participants/events
– Findings in line with previous syst review
– Findings robust in sensitivity analyses
• Limitations
– Based on quasi-experimental studies
– Little evidence on policies other than smoke-free legislation
– Findings not always consistent
– Unable to assess publication bias
76. second-hand
smoke exposure
smoking cessation
and initiation
smoke-free
legislation
smoking during
pregnancy
SHS exposure
during pregnancy
perinatal
outcomes
SHS exposure
during childhood
child health
outcomes
Faber et al. npj Prim Care Respir Med 2016
77. second-hand
smoke exposure
social norm
changes
smoking cessation
and initiation
smoke-free
legislation
smoking during
pregnancy
SHS exposure
during pregnancy
perinatal
outcomes
SHS exposure
during childhood
child health
outcomes
Faber et al. npj Prim Care Respir Med 2016
78. second-hand
smoke exposure
social norm
changes
smoking cessation
and initiation
smoke-free
legislation
smoking during
pregnancy
SHS exposure
during pregnancy
perinatal
outcomes
SHS exposure
during childhood
child health
outcomes
Faber et al. npj Prim Care Respir Med 2016
Thirdhand smoke?
79. Knowledge gaps
• Impact of several MPOWER / endgame
policies on child health not known
• Synergistic effect of policies?
• Impact on inequalities?
• Cost-effectiveness?
• Low and middle income countries?
80. Implications
• Smoke-free legislation needs to be
implemented across the globe
• Comprehensiveness is important
• Other tobacco control policies also likely to
benefit child health and therefore
supported
• Child health angle important for advocacy
• Continuous impact monitoring is essential
83. Prof. Aziz Sheikh
Prof. Chris Millett
Prof. Johan Mackenbach
Dr. Sanjay Basu
Timor Faber
Funders:
Arun Kumar
84. • Infant mortality decreased by
– 0.23 per 1,000 (95%CI 0.37, 0.09) per 1€ increase in cig price
– 0.16 per 1,000 (95%CI 0.30, 0.03) per 1€ increase in cig price in previous
year
• Infant mortality increased by
– 0.07 per 1,000 (95%CI 0.01, 0.13) for every 10% increase in minimum-
median cig price differential in previous year
• Infant deaths avoided by price increase (2005-2014):
9,208 (95%CI 8,601 to 9,814)
• Infant deaths avoidable by reducing price differential (2005-2014):
3,195 (95%CI 3,017 to 3,372)
85. Poll Question #4
The information presented today was
helpful
A. Strongly agree
B. Agree
C. Neutral
D. Disagree
E. Strongly disagree
86. What can I do now?
Visit the website; a repository of over 5,000+ quality-rated systematic reviews
related to the effectiveness of public health interventions. Health Evidence™ is
FREE to use.
Register to receive monthly tailored registry updates AND monthly newsletter
to keep you up to date on upcoming events and public health news.
Tell your colleagues about Health Evidence™: helping you use best evidence to
inform public health practice, program planning, and policy decisions!
Follow us @HealthEvidence on Twitter and receive daily public health review-
related Tweets, receive information about our monthly webinars, as well as
announcements and events relevant to public health.
Encourage your organization to use Health Evidence™ to search for and apply
quality-rated review level evidence to inform program planning and policy
decisions.
Contact us to suggest topics or provide feedback.
info@healthevidence.org
87. Poll Question #5
What are your next steps? [Check all
that apply]
A. Access the full text systematic review
B. Access the quality assessment for the
review on www.healthevidence.org
C. Consider using the evidence
D. Tell a colleague about the evidence